CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 14 enrolled
Drug / intervention
dl-Methylphenidate plus Cannabidiol +1 moredrug
Likely dose
dl-Methylphenidate plus Cannabidiol 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04603391
NCT04603391Phase 4Completed
CompareCT.gov

An Assessment of the Drug Interaction Potential Between Oral Cannabidiol (Epidiolex®) and the CES1 Substrate Methylphenidate in Healthy Volunteers

University of Florida·interventional·Posted Oct 26, 2020·Updated Jul 18, 2024

In Brief

A Phase 4 clinical trial evaluating dl-Methylphenidate plus Cannabidiol and dl-Methylphenidate plus Cannabidiol Placebo solution for Drug Interaction. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The proposed study will assess the drug interaction potential between oral cannabidiol (Epidiolex®) and the carboxylesterase 1 (CES1) substrate methylphenidate (Ritalin®) in 12 healthy research subjects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug Interaction
CountriesUnited States
CollaboratorsConsortium for Medical Marijuana Clinical Outcomes Research

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedOct 26, 2020
Enrollment StartFeb 25, 2021
Primary CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.7 years ago

Interventions

dl-Methylphenidate plus Cannabidioldrug

Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution

dl-Methylphenidate plus Cannabidiol Placebo solutiondrug

Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution